drugset / Trial / NCT01135446
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
RandomizedParallel-groupOpen-label
Summary
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 0.001 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 0.01 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 0.1 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 0.3 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 1 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 2.5 mg | Oral |